Drug Profile
Research programme: benign prostatic hyperplasia therapeutics - Recordati
Alternative Names: REC 0035Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Recordati
- Class
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in Italy